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Atrial fibrillation (AF) is a major worldwide public health problem, and AF in association with valvular heart disease (VHD) is also com-
mon. However, management strategies for this group of patients have been less informed by randomized trials, which have largely focused
on ‘non-valvular AF’ patients.
Thrombo-embolic risk also varies according to valve lesion and may also be associated with CHA2DS2VASc score risk factor components,
rather than only the valve disease being causal.
Given marked heterogeneity in the definition of valvular and non-valvular AF and variable management strategies, including non-vitamin K
antagonist oral anticoagulants (NOACs) in patients with VHD other than prosthetic heart valves or haemodynamically significant mitral
valve disease, there is a need to provide expert recommendations for professionals participating in the care of patients presenting with AF
and associated VHD.
To address this topic, a Task Force was convened by the European Heart Rhythm Association (EHRA) and European Society of
Cardiology (ESC) Working Group on Thrombosis, with representation from the ESC Working Group on Valvular Heart Disease, Heart
Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad
Latinoamericana de Estimulacion Cardıaca y Electrofisiologıa (SOLEACE) with the remit to comprehensively review the published evi-
dence, and to publish a joint consensus document on the management of patients with AF and associated VHD, with up-to-date consen-
sus recommendations for clinical practice for different forms of VHD.
This consensus document proposes that the term ‘valvular AF’ is outdated and given that any definition ultimately relates to the
evaluated practical use of oral anticoagulation (OAC) type, we propose a functional Evaluated Heartvalves, Rheumatic or Artificial
(EHRA) categorization in relation to the type of OAC use in patients with AF, as follows: (i) EHRA Type 1 VHD, which refers to AF patients
with ‘VHD needing therapy with a Vitamin K antagonist (VKA); and (ii) EHRA Type 2 VHD, which refers to AF patients with ‘VHD need-
ing therapy with a VKA or a Non-VKA oral anticoagulant (NOAC)’, also taking into consideration CHA2DS2VASc score risk factor com-
ponents.
This consensus document also summarizes current developments in the field, and provides general recommendations for the management
of these patients based on the principles of evidence-based medicine.
...................................................................................................................................................................................................
Keywords Atrial fibrillation • Valvular heart disease • Mitral stenosis • Mechanical prosthetic heart valves • Thrombo-
embolism • Stroke • Stroke prevention • Anticoagulation • Vitamin K antagonists • Non-vitamin K antago-
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Preamble and valvular heart
disease definition
Atrial fibrillation (AF) is a major public health problem1 with global
prevalence rates (per 1000000 population) in 2010 being 596.2
(95% uncertainty interval (UI), 558.4–636.7) in men and 373.1
(95% UI, 347.9–402.2) in women; the incidence rates increased
to 77.5 (95% UI, 65.2–95.4) in men and 59.5 (95% UI, 49.9–74.9)
in women.2 Worldwide, AF in association with valvular heart dis-
ease (VHD) is also common, and management strategies for
this group of patients have been less addressed by randomized
trials. The latter have largely focused on ‘non-valvular AF’ patients
leading to major uncertainties over how to define (and treat) such
patients.
There is also an important heterogeneity in the definition of valvu-
lar and non-valvular AF.3 Some physicians assume that any valve dis-
ease should be considered as ‘valvular’ AF. Others consider that only
mechanical valve prosthesis and rheumatic mitral stenosis should be
defined as ‘valvular’ AF.
The term valvular AF has been arbitrarily applied and the 2016
ESC guidelines have avoided the term ‘valvular AF’ and refer sim-
ply to ‘AF related to hemodynamically significant mitral stenosis
or prosthetic mechanical heart valves’.4 AF clearly leads to an
incremental risk for thromboembolism in patients with mitral
valve stenosis, but there are limited data for other valvular dis-
eases. Another proposal is to use the acronym MARM-AF as a
simple acronym to designate ‘Mechanical and Rheumatic Mitral
AF’ as an alternative to term ‘valvular AF’ to designate the clinical
scenarios for which at the non-vitamin K antagonist oral anticoa-
gulants (NOACs) are not indicated.5
For this document we recognize the uncertainty in terminology,
and our scope largely relates to AF related to ‘hemodynamically sig-
nificant’ rheumatic VHD (ie. severe enough to impact on patient’s
survival or necessitates an intervention or surgery) or prosthetic
mechanical heart valves. Nonetheless, thrombo-embolic (TE) risk
varies according to valve lesion and may be associated with
CHA2DS2VASc score risk factor components, rather than the valve
disease per se being causal.6,7 TE risk may also be influenced not only
by type but also the severity of the lesion. For example, the degree of
mitral regurgitation may matter when it comes to risk of TE as some
studies suggest that mild (Grade 1) mitral regurgitation is associated
with a 2.7-fold increased risk of stroke/TE, while severe forms may
possibly have a ‘protective’ effect (HR = 0.45 for stroke and 0.27 for
LA stasis.8 An appropriate definition of ‘valvular AF’ would need to
identify a subgroup of patients with similar pathophysiology of
thrombo-embolism, TE risk, and treatment strategies6,9; however,
this would be challenging given the major heterogeneity of the
condition.
This consensus document proposes that the term ‘valvular AF’ is
outdated and given that any definition ultimately relates to the eval-
uated practical use of oral anticoagulation (OAC) type, we propose a
functional EHRA (Evaluated Heartvalves, Rheumatic or Artificial) cat-
egorization in relation to the type of OAC use in patients with AF, as
follows:
Evaluated Heartvalves, Rheumatic or Artificial (EHRA) Type 1,
which refers to AF patients with ‘VHD needing therapy with a
Vitamin K antagonist (VKA)’
• Mitral stenosis (moderate-severe, of rheumatic origin)
• Mechanical prosthetic valve replacement
[EHRA Type I VHD is broadly similar to the previously described
MARM-AF.]
Evaluated Heartvalves, Rheumatic or Artificial (EHRA) Type 2
VHD, which refers to AF patients with ‘VHD needing therapy with a
VKA or a NOAC’, also taking into consideration CHA2DS2VASc
score risk factor components:
• Mitral regurgitation







• Bioprosthetic valve replacements
• Trans-aortic valve intervention (TAVI)
This classification would have the advantage that it may easily
evolve or be updated (type 1 may become type 2 or vice versa)
when there are new results. For example, transcatheter mitral valve
interventions (TMVI, e.g. to include both MitraClip and Mitral valve
replacement) are emerging as a possible therapeutic options,10 but
more data are awaited especially in relation to OAC use.
A recent physicians survey3 reported marked heterogeneity in the
definition of valvular and non-valvular AF and variable management
strategies, including NOACs in patients with VHD other than pros-
thetic heart valves or haemodynamically significant mitral stenosis.
Thus, there is a need to provide expert recommendations for profes-
sionals participating in the care of patients presenting with AF and
associated VHD. These may include rheumatic VHD, mechanical or
biological prosthetic valves and percutaneous aortic valve implanta-
tion (TAVI), as well as those having undergone mitral valve repair.
Whilst hypertrophic cardiomyopathy is sometimes discussed in asso-
ciation with valvular AF, this would not be addressed in this document,
given specific guidelines on the management of this condition.11
To address this topic, a Task Force was convened by the European
Heart Rhythm Association (EHRA) and European Society of
Cardiology (ESC) Working Group on Thrombosis, with representa-
tion from the ESC Working Group on Valvular Heart Disease, Heart
Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS),
South African Heart (SA Heart) Association and Sociedad
Latinoamericana de Estimulacion Cardıaca y Electrofisiologıa
(SOLEACE) with the remit to comprehensively review the published
evidence, and to publish a joint consensus document on the manage-
ment of patients with AF and associated VHD, with up-to-date con-
sensus recommendations for clinical practice.
This document summarizes current developments in the field, and
provides general recommendations for the management of these
patients based on the principles of evidence-based medicine.
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Rather than ‘valvular AF’ a more functional Evaluated Heartvalves,
Rheumatic or Artificial (EHRA) categorization in relation to the type
of OAC use is recommended in patients with AF, as follows:
(i) EHRA Type 1 VHD, which refers to AF patients with ’VHD
needing therapy with a Vitamin K antagonist (VKA); and
(ii) EHRA Type 2 VHD, which refers to AF patients with
‘VHD needing therapy with a VKA or a Non-VKA oral
anticoagulant (NOAC), also taking into consideration
CHA2DS2VASc score risk factor components.
Evidence review
Members of the Task Force were asked to perform a detailed litera-
ture review, weigh the strength of evidence for or against a particular
treatment (or procedure), and include estimates of expected health
outcomes where data exist. Patient-specific modifiers, comorbidities,
and issues of patient preference that might influence the choice of
particular tests or therapies are considered, as are frequency of
follow-up and cost effectiveness. In controversial areas, or with
regard to issues without evidence other than usual clinical practice, a
consensus was achieved by agreement of the expert panel after thor-
ough deliberations. This document was prepared by the Task Force
with representation from EHRA, HRS, APHRS, and SOLAECE. The
document was peer-reviewed by official external reviewers repre-
senting EHRA, HRS, APHRS, and SOLAECE.
Consensus statements are evidence-based, and derived primarily
from published data. Current systems of ranking level of evidence are
becoming complicated in a way that their practical utility might be com-
promised.12 We have, therefore, opted for an easier and, perhaps, more
user-friendly system of ranking that should allow physicians to easily
assess current status of evidence and consequent guidance (Table 1).
Thus, a ‘green heart’ indicates a recommended statement or rec-
ommended/indicated treatment (or procedure) and is based on at
least one randomized trial, or is supported by large observational evi-
dence that it is beneficial and effective. A ‘yellow heart’ indicates gen-
eral agreement and/or scientific evidence favouring a statement or
the usefulness/efficacy of a treatment or procedure. A yellow heart
may be supported by randomized trials based on small number of
patients or not widely applicable. Treatment strategies for which
there have been scientific evidence that they are potentially harmful
and should not be used are indicated by a ‘red heart’.
EHRA grading of consensus statements does not have separate
definitions of Level of Evidence. The categorisation used for consen-
sus statements (used in consensus documents) should not be consid-
ered as being directly similar to that used for official society guideline
recommendations which apply a classification (I–III) and level of evi-
dence (A, B, and C) to recommendations in official guidelines.
Finally, this is a consensus document that includes evidence and
expert opinions from several countries. The anticoagulation
approaches discussed may, therefore, include drugs that do not have
the approval of governmental regulatory agencies in all countries.
Relationships with industry and other
conflicts
It is EHRA/ESC policy to sponsor position papers and guidelines
without commercial support, and all members volunteered their
time. Thus, all members of the writing group as well as reviewers
have disclosed any potential conflict of interest in detail, at the end of
this document.
Epidemiology of valvular atrial
fibrillation and implications for
stroke/thrombo-embolism
The reported prevalence of AF varies by geographical region.2 In
Australian, North American and European studies, approximately
1–2% of adults have AF.13–15 In Asians, the reported prevalence of
AF ranges from 0.1–4.0% in the community and 2.8–14% in hospital-
based studies.16
Nonetheless, robust data on the epidemiology of patients with AF
and associated VHD are limited. Examples of available data from
some global registries and large trials are reported in Supplementary
material online, Table S1. In the RE-LY AF Registry which enrolled
patients presenting to an emergency department with AF at 164 sites
in 46 countries, rheumatic heart disease was present in 2.2% of North
American patients, in comparison with 21.5% in Africa and 31.5% in
India7; interestingly thrombo-embolism rates were related to clinical
risk profile, as expressed by CHADS2 score, irrespective of the pres-
ence of rheumatic VHD. Detailed data on the geographic distribution
of valvular AF are also reported in the Supplementary material online.
.................................................................................................
Table 1 Scientific rationale of recommendations
Definitions where related





Scientific evidence that a treat-
ment or procedure is benefi-
cial and effective. Requires at
least one randomized trial, or
is supported by strong obser-
vational evidence and authors’




General agreement and/or scien-
tific evidence favour the use-
fulness/efficacy of a treatment
or procedure. May be sup-
ported by randomized trials
based on small number of
patients or not widely
applicable.
May be used or
recommended
Scientific evidence or general
agreement not to use or rec-





This categorization for our consensus document should not be considered as
being directly similar to that used for official society guideline recommendations
















There is a general agreement that AF is independently associated with
thrombotic diathesis.17 The drivers include the three elements of the
Virchow’s triad: blood flow alterations, endocardial injury and changes in
blood constituents.18 In fact, according to the recently published EHRA/
HRS/APHRS/SOLAECE consensus document, atrial tissue in VHD is
characterized, at a histopathological level, by a combination of cardio-
myocyte and fibrotic changes.19 Co-morbidities present in most AF
patients may contribute to enhance thrombotic risk by pro-inflamma-
tory/pro-atherogenic mechanisms. An overview of the pathophysiology
of thrombogenesis in AF in haemodynamically significant mitral stenosis
and/or mechanical heart valves prosthesisis shown in Figure 1.
The risk of TE is increased in patients with AF and mechanical
valve, mild-to-severe mitral stenosis20 and left atrium dilatation, as
compared to non-valvular AF,6 suggesting differences among the
pathogenic mechanisms contributing to thrombosis in each of these
AF conditions. It is generally thought that Virchow’s triad is triggered
by the turbulent flow and the endothelial injury that accompanies
valvular AF. On top of this, AF prosthetic valves (particularly mechan-
ical prosthesis) induce thrombin generation through the activation of
both the tissue factor (TF) and the contact coagulation pathways.21
Figure 1 Pathophysiology of thrombogenesis in atrial fibrillation (AF) related prosthesis and/or mitral valve diseases. In valvular-AF there is a propen-
sity to thrombosis because of the presence of the Virchow’s triad components which, in turn, are found likely boosted by patients’ co-morbid conditions.
The risk of thrombosis, however, is enhanced because of the presence of prosthetic valves which activate the coagulation cascade (both the intrinsic and
extrinsic pathway) leading to thrombin production (a strong platelet agonist); and, although to a lesser extent, because of the considerable degree of
mitral stenosis which induces flow turbulences capable of inducing platelet activation. Finally, AF also frequently occurs in patients with severe aortic
stenosis, which can be associated to the Heyde’s syndrome due to Von Willebrand Factor (VWF) consumption leading to an acquired bleeding disorder.
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Surgical heart valve replacement surgery induces tissue damage with
TF release leading to extrinsic coagulation pathway activation after
binding to plasma Factor (F) VII/FVIIa. Moreover, the exposure of
valve leaflets, struts and/or sewing ring to the circulating blood22 can
activate the contact (intrinsic) coagulation pathway. Both intrinsic
and extrinsic pathways converge factor X (FX) activation and then
the transformation of prothrombin into thrombin (FIIa) and forma-
tion of the fibrin mesh. The vitamin K antagonist (VKA), warfarin, by
blocking the formation of the vitamin K-dependent clotting FVII, FIX,
FX, and FII prevents the activation of the coagulation cascade at the
extrinsic and intrinsic pathway levels.
In addition to the thrombogenic contribution of plasma coagula-
tion in valvular AF, platelet activation may possibly contribute,
although to a much lesser extent, to promote thrombogenesis, par-
ticularly in mild-to-severe mitral stenosis. It is also possible that mod-
erate to severe mitral stenosis causes increased blood stasis, due to
the severe dilatation of the left atrium occurring in this condition.
Finally, acquired type IIA von Willebrand disease and bleeding com-
plications can be associated with severe aortic stenosis due to high-
molecular weight multimer consumption.23
Oral anticoagulation with vitamin
K antagonists in patients with AF
and prosthetic heart valves,
including bioprostheses
Mechanical heart valves
Oral anticoagulation (OAC) with VKA is crucial for prevention of TE
in patients with mechanical heart valves, regardless the presence or
absence of AF. The ESC guidelines24 establish the risk of TE in patients
with mechanical valves according to valve type and position, and also
according to the individual patient risk profile or comorbidities.
Warfarin and other VKA are the most widely used OACs, and are
titrated according to international normalized ratio (INR) range and
target value which is also related with associated risk factors (Table 2).
The duration of antithrombotic therapy also varies according to a
number of factors. Lifelong anticoagulant treatment is indicated for all
patients with mechanical valves and those with bioprosthetic valves
or native valve disease with >_1 additional risk factors.
Clinical trials with VKA are sparse and recommendations are
mostly based on old trials, with the oldest types of mechanical valve
prostheses, and AF patients were excluded.
Patients with bioprostheses and additional risk factors for embo-
lism (AF, venous TE, hypercoagulable state, or with a lesser degree of
evidence, severely impaired left ventricular function) require life-long
OAC. The use of NOACs instead of warfarin in this setting is
accepted by the more recent document of recommendations by
EHRA25 in spite of a lack of randomized clinical trials (RCT)26–28 (see
Antithrombotic therapy in patients with AF undergoing TAVI or
LAAO section for NOACs and bioprosthesis).
Bioprostheses
After biological valve replacement, thrombo-embolic risk is esti-
mated between 0.6 to 3.3% per year without anticoagulation, after
the third month.29 The thrombo-embolic risk associated with a bio-
prosthesis and sinus rhythm is higher in the first 3 months after sur-
gery, the risk being almost eliminated in anticoagulated patients for
aortic bioprosthesis, but remaining higher in patients with a mitral
bioprosthesis.30,31 The benefit of an initial anticoagulant treatment
following aortic valve replacement with a bioprosthesis and no AF is
however debated.32–34
Overall AF patients with a bioprosthesis had a non-significantly
higher risk of stroke/TE events compared with patients with non-
valvular AF, and VKA use was independently associated with a
lower risk of thrombo-embolic events (hazard ratio 0.83, 95%
CI 0.71–0.98).35
One small pilot study compared Dabigatran Versus Warfarin After
Bioprosthesis Valve Replacement for the Management of Atrial
Fibrillation Postoperatively (DAWA Pilot Study) but small numbers
preclude definitive conclusions.36
Recent small studies also suggest that NOACs can be a reasonable
alternative to VKA in patients with AF and remote bioprosthetic
valve implantation,26,37 however larger studies are needed to define
the safety and efficacy profile. Data on thromboprophylaxis in
patients with AF and TAVI, which is actually the insertion of a bio-
prosthesis, are preliminary38 and discussed in detail elsewhere in the
document section.
Mitral valve repair
Patients undergoing mitral valve repair have a small risk of TE,39 with
the highest risk of TE occurring during the first year after surgery.
Guidelines therefore recommend OAC during the first 3–6 months
after surgery.40 However, only limited data are available on the effi-
cacy of warfarin therapy in the early stages after valve surgery, and
the use of short-term VKAs in patients with mitral valve annuloplasty
is also controversial. It is therefore not clear whether patients with
AF in addition to valve repair are markedly different from the patients
with AF and no VHD.6,21
North American and European guidelines have a different position
on this issue, the former considering AF is ‘valvular AF’ whilst ESC
guidelines do not.32,41
.................................................................................................
Table 2 Target international normalized ratio for





Risk factor >_ 1
Low Carbomedics, Medtronic
Hall, St Jude Medical,
ON-X
3.0







*Risk factors: previous thromboembolism; AF; mitral stenosis of any degree; left















Indications of ‘add on’ antiplatelet
therapy in patients with atrial
fibrillation and prosthetic
mechanical heart valves
Arterial TE and valve thrombosis are 12%/year and 22%/year, for
mechanical valve prosthesis in the aortic and mitral position, respec-
tively, in patients without VKA prophylaxis.29 The residual risk ranges
from 0.5%/year, to 2.5%/year,29,42–44 in VKA-treated patients without
additional cardiovascular risk factors such as AF. A higher incidence is
associated with the mitral (2%/year) vs. the aortic (1%/year) posi-
tion, depending also on the type of valve and VKA intensity.29,43,44 AF
and/or other risk factors (e.g. heart failure, even without AF) increase
TE risk by four-fold, from 4% up to 8%/year,45–47 even on adequate
VKA treatment.45,46
Given this high residual TE risk, RCT have compared VKA alone vs.
VKA combined with different aspirin doses and/or dipyridamole29,48,49
(Table 3).
Despite major methodological limitations of these studies includ-
ing small sample size, heterogeneities in thrombotic risk level at study
entry and anticoagulation intensity, inconsistencies in safety and effi-
cacy endpoint definitions,48 there may possibly be some benefit of
adding low-dose aspirin (between 75 and 200 mg daily) to VKA in
patients with mechanical valve prosthesis and additional risk factors
including AF29,48,54 (Table 3). This approach lowered TE complica-
tions in the majority of studies,29,45,46,48,54 and two meta-analyses
showed60% relative risk reduction (RRR) of TE and50% RRR of
all-cause mortality48,49 (Table 3). Nonetheless, the relative risk of
major bleeding with VKAs plus antiplatelet therapy increases by
58% across studies including aspirin daily doses from 100 to
1000 mg48,49 and high dose dipyridamole alone or with aspirin.48
Importantly, major bleeding appears significantly affected by aspirin
dose: the association with low dose (100 mg) shows a bleeding risk
significantly lower than higher doses50,52 and not significantly different
from VKA alone (OR = 0.96; 95% CI 0.60–1.55; 2.58; 95% CI 1.43–
2.55 for low and high doses vs. VKA, respectively, P = 0.002 for the
high aspirin dose combination vs. VKA) with similar efficacy
(Table 3).48,50 Thus, VKA plus low-dose aspirin (75–100 mg daily) for
the association of mechanical prosthetic valve and AF, is
recommended by the AHA/ASA/ACCP as a class I (level A or B) rec-
ommendation,42,44,55,56 but as a class IIb C recommendation by the
ESC.
When the aspirin/VKA combination is used, anticoagulation should
be titrated taking into account the type of valve, the position, and
comorbidities. The target INR for AF patients with aortic mechanical
prosthetic valve on VKA and low-dose aspirin should be 2.5 (range
2.0–3.0), with close attention to the quality of anticoagulation con-
trol, with time in therapeutic range (TTR) >65–70%. This applies to
low-thrombogenicity valves, including Carbomedics, Medtronic Hall,
St Jude Medical, ON-X; but there is insufficient data for other valves,
even if bileaflet.
Whether the INR target should be 2.5 (range 2–3) or 3 (range
2.5–3.5) in AF patients with mitral prosthetic valve on both VKA and
low-dose aspirin is less clear. High intensity VKA (i.e. INR range 3–4
or higher), combined with aspirin, has been consistently associated
with higher major bleeding and comparable benefit as lower intensity
VKA with aspirin.51,52,57
Consensus statements
Evidence for non-vitamin K
antagonist oral anticoagulants use
in patients with atrial fibrillation
and valvular heart disease
Subgroups from the recent non-vitamin
K antagonist oral anticoagulant trials
The efficacy and safety of NOACs for the prevention of stroke/sys-
temic embolic events (SSEE) in patients with non-valvular AF has
been established by the pivotal randomized trials.58,60–63 These trials
excluded patients with significant mitral stenosis or prosthetic






• Well managed VKA monotherapy with
good anticoagulation control (e.g. TTR
>65–70%), is generally recommended,
taking into account the type of valve, the
position, and additional risk factor(s),
including atrial fibrillation.
24
• Patients with a bioprosthetic valve and






• In patients with a mechanical pros-
thetic valve and concomitant AF with
vascular disease, VKA plus low-dose
aspirin (75–100 mg daily) may be con-
sidered in the absence of high bleed-
ing risk.
53,54,56–69
 In patients with a mechanical pros-
thetic valve and AF, when VKA plus
aspirin are used, the INR should be
kept between 2.0 and 3.0 (target 2.5),
given the high bleeding risk of the
combination and the lack of evidence
of greater protection with higher
intensity VKA (INR range 3–5 or
above).
51,56,63
• High doses of aspirin (>_325 mg) in
association with VKA at any intensity
must be avoided.
51,60
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the trial)28,59,64,65 with other clinically significant non-rheumatic VHD,
including mitral regurgitation (MR), aortic regurgitation (AR), aortic
stenosis (AS), mild mitral stenosis (MS) or prior valve surgery (bio-
prosthetic valves or valve repair) (Table 4). There are limited or no
data on other options, such as MitraClip or other TMVI, and thus,
NOACs should not be used in these patients.
Variable inclusion/exclusion criteria across the NOACs trials
reflect the prevailing lack of a clear-cut definition of valvular AF.6
Patients with VHD of non-rheumatic origin are prevalent in clinical
practice,66 and physicians may often deny NOACs to eligible AF
patients due to uncertainty over whether the patient has valvular or
non-valvular AF.3
There are no randomized trials on NOACs in AF patients with
VHD. In the Randomized Evaluation of Long-Term Anticoagulation
Therapy (RE-LY),59 Rivaroxaban Once Daily Oral Direct Factor Xa
Inhibition Compared with Vitamin K Antagonism for Prevention of
Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF),64
Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE)65 and Effective
Anticoagulation with factor Xa Next Generation in Atrial Fibrillation-
Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48)28
trial subgroup analyses, non-valvular AF patients with VHD were
older, had more comorbidities (including renal dysfunction), more
persistent/permanent AF and higher cardioembolic and bleeding risks
than patients without VHD. Whilst the use of aspirin was broadly
similar, prior VKA use was more common among patients with VHD.
Irrespective of the treatment arm (i.e. warfarin or a NOAC), VHD
patients generally experienced worse outcomes (stroke and systemic
TE, major bleeding or all-cause death) in comparison to non-VHD
patients (Table 5). Nonetheless, the efficacy of NOACs in reduction
of SSEE or all-cause mortality was consistent among patients without
or with VHD (irrespective of the VHD subtype). Likewise, the safety
of NOACs in terms of lower risk of major bleeding or ICH was con-
sistent irrespective of VHD status, excluding the significantly higher
rates of major bleeding in VHD patients (particularly those with
aortic stenosis, or mitral or aortic regurgitation)69 treated with rivar-
oxaban compared to warfarin (Table 5). Importantly, there are no
head-to-head comparisons for any NOAC vs. VKA in AF patients
with moderate to severe mitral stenosis; as mentioned, these patients
were not enrolled in the NOACs trials.
The number of patients with any prior valve surgery (i.e. bio-
prosthetic valves or valve repair) exposed to rivaroxaban, apixa-
ban or edoxaban in the ROCKET-AF, ARISTOTLE or ENGAGE
AF-TIMI 48 trials, respectively, was very low (Table 4).
Nevertheless, as reported for apixaban and edoxaban,26,68 there
was no statistically significant interaction between the presence of
a bioprosthetic heart valve and the respective NOAC effects
(Table 5), thus suggesting that apixaban or edoxaban may possibly
be alternatives to warfarin in AF patients with bioprosthetic valves
implanted >_3 months ago.
....................................................................................................................................................................................................................
Table 4 Inclusion/exclusion criteria pertinent to valvular heart disease in the pivotal NOAC trials in patients with
‘non-valvular’ AF and valvular disease type distribution across the trials
Inclusion ()/exclusion (–) criteria RE-LY61 ROCKET-AF58 ARISTOTLE60 ENGAGE-AF62 AVERROES63
Prosthetic heart valve(s)
Mechanical – – – – –
Bioprosthesis – –   
Prior surgical repaira –    
Moderate-to-severe MS – – – – –
Other significant valve diseaseb –    –
Mild-to-moderate valve disease     
Subgroups with a cardiac valve diseasec RE-LY58 ROCKET-AF64 ARISTOTLE67 ENGAGE-AF28
Total n (%) 3950 (21.8) 2003 (14.1) 4808 (26.4) 2824 (13.4) NR
Moderate/severe MR 3101 (78.5) 1756 (87.7) 3526 (73.3) 2250 (79.6) NR
Moderate/severe AR 817 (20.7) 486 (24.3) 887 (18.4) 369 (13.0) NR
Moderate/severe AS 471 (11.9) 215 (10.7) 384 (8.0) 165 (5.8) NR
Other 1179 (6.5) 11 (0.6)d 2124 (44.2) NR NR
Mild MS 193 (4.9) NR 131 (2.7) 254 (9.0) NR
Prior valve surgery (excluding mechanic
prosthetic heart valve)
Not applicable 106 (5.3) 251 (5.2) 325 (11.5) NR
Valve repair — 42 (2.1%) NR 123 (4.3) NR
Valvuloplasty — 64 (3.2%) NR 19 (0.7) NR
Bioprosthetic valves — Not applicable 82 (1.7) 191 (6.8) NR
AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; MR, mitral regurgitation; MS, mitral stenosis; NOAC, non-vitamin K antagonist oral anticoagulant; NR, not
reported.
aAnnuloplasty, Commisurotomy, Valvuloplasty, etc.
bClinically significant, but not requiring immediate surgery repair.
cCategories are not mutually exclusive.
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A meta-analysis70 of the VHD sub-groups from the RE-LY,
ROCKET-AF, ARISTOTLE and ENGAGE AF-TIMI 48 trials broadly
confirmed the findings shown in Table 5. Overall, AF patients with
VHD had non-significantly higher rate of SSEE (RR 1.13; 95% CI,
0.99–1.28) and significantly higher rates of major bleeding (RR 1.34;
95% CI, 1.13–1.49) and all-cause death (RR 1.34; 95% CI, 1.13–1.59)
than patients without VHD.
Compared with warfarin, the use of NOACs (i.e. rivaroxaban,
apixaban or higher doses of dabigatran or edoxaban) was associated
with consistently lower rates of SSEE regardless of the presence or
absence of VHD (RR 0.70; 95% CI, 0.58–0.86 and 0.84; 95% CI, 0.75–
0.95, respectively; interaction P = 0.31), similar major bleeding rates
(VHD RR 0.93; 95% CI, 0.67–1.27 and no-VHD RR 0.85; 95%
CI 0.70–1.02, interaction P = 0.63), consistently lower rates of ICH
(VHD RR 0.47; 95% CI, 0.24–0.93 and no-VHD RR 0.49; 95%
CI, 0.41–0.59, interaction P = 0.91) and higher all-cause death rate in
VHD patients (RR 1.01; 95% CI, 0.90–1.14) than in those without
VHD (RR 0.88; 95% CI, 0.82–0.94), interaction P = 0.03,70 In the anal-
ysis that also included the lower doses of dabigatran and edoxaban,
the magnitude of SSEE risk reduction with NOACs vs. warfarin was
slightly reduced, as well as the rates of major bleeding and ICH, but
there were no significant subgroup interactions by VHD status.
Overall, the presence of VHD did not affect the relative protective
effect of NOACs compared with warfarin in terms of SSEE and
major bleeding. These findings were further supported by another
meta-analysis of the four NOACs yielding identical results.71 Of note,
both meta-analyses reported significant treatment effect heterogene-
ity regarding the analysis of major bleeding.
With the exclusion of patients with moderate-to-severe mitral
stenosis, prosthetic mechanical heart valve, TAVI or TMVI, who
were not enrolled in the non-valvular AF trials, the aforemen-
tioned subgroup and meta-analyses may suggest that AF patients
with VHD would experience at least the same benefit from
NOACs as patients without VHD. However, due to limitations
inherent to these types of analyses, further RCTs are required in
AF patients with VHD before recommendations can be given (see
Tables 4 and 5).
Prosthetic mechanical heart valves:
Randomized, Phase II Study to Evaluate
the Safety and Pharmacokinetics of Oral
Dabigatran Etexilate in Patients after
Heart Valve Replacement
Mechanical valve prosthesis trigger complex mechanisms of throm-
bogenesis and are associated with a very high cardioembolic risk
requiring chronic OAC even in the absence of AF. Animal studies on
mechanical valve implantation using first the direct FIIa inhibitors mel-
agatran72 and then dabigatran73,74 as well as the phase III data from
the RE-LY trial61 informed the only study to date on a NOAC in
patients with mechanical heart valves.
The Randomized, Phase II Study to Evaluate the Safety and
Pharmacokinetics of Oral Dabigatran Etexilate in Patients after
Heart Valve Replacement (RE-ALIGN) trial was a phase-II, con-
trolled, dose-finding, open-label study75 randomizing (2:1)
patients with aortic (n = 172; 68%) or mitral (n = 71; 28%) mechan-
ical valve replacement, or both (n = 9; 4%) to dabigatran or
adjusted-dose warfarin (target INR 2.0–3.0 or 2.5–3.5 in aortic or
mitral position, respectively). The initial dabigatran dose of 150,
220, or 300 mg b.i.d. (selected according to renal function) was
further adjusted over 12 weeks to achieve the primary study out-
come—a trough plasma concentration >_50 ng/mL, based on the
pharmacokinetic model from the RE-LY trial. Most patients (79%)
received study drug 5–7 days after surgery, and 23% of patients
had AF. The RE-ALIGN study was prematurely terminated after
randomizing 252 of 405 planned patients, due to an excess in
stroke (5% vs. 0%), valve thrombosis (3% vs. 0%) and major bleed-
ing events (4% vs. 2%) in the dabigatran arm, after a mean dabiga-
tran exposure of 20 weeks. Different explanations have been
proposed, including inadequate dabigatran plasma concentrations,
different pharmacodynamics of dabigatran and warfarin, excessive
activation of the contact coagulation pathway induced by the sew-
ing ring in the early postoperative course, a higher inter-individual
variability in the dabigatran arm and differences in predicted vs.
observed drug concentrations in the RE-LY vs. RE-ALIGN.75 A
recent in vitro study suggested that the dabigatran trough plasma
concentration required to reduce valve-induced FIIa generation
should be much higher than 50 ng/mL (that is, 260 ng/mL) corre-
sponding to a 620 mg b.i.d. dosing.68 At present, all AF patients







• The use of the NOACs in patients
with AF and mechanical valve pros-
thesis is contraindicated.
76
• Randomized clinical trials testing the
efficacy and safety of direct oral FXa
inhibitors in patients with AF and
mechanical heart valved prosthesis
are lacking. Until more data are avail-
able, rivaroxaban, apixaban, and edox-
aban are contraindicated in such
patients.
. . .
• Until more data are available, AF
patients with any degree of rheumatic
mitral valve stenosis and those with
moderate-to-severe non-rheumatic
mitral stenosis should not be treated
with NOACs.
. . .
• The efficacy and safety of NOACs for
stroke/SE prevention may be similar
in AF patients with and without con-
servative valve surgery such as annu-
loplasty, commissurotomy or
valvuloplasty, or bioprosthetic valves
based on small numbers of patients in

















patients with atrial fibrillation
undergoing trans-aortic valve




Most ischaemic events after TAVI are cerebrovascular, and for these
AF is a strong contributor.77 AF is common among high-risk patients
with severe aortic stenosis undergoing TAVI, and is associated with a
>2-fold increased risk of all-cause and cardiovascular death, irrespec-
tive of the type of AF.78 In addition, the implanted valve adds a
prothrombotic environment, which would accentuate the cardioem-
bolic risk. Of importance, the gradient of risk directly correlates with
the CHA2DS2-VASc score, which is usually used to aid decision-
making as whether to initiate OAC.77 At least 30% of the TAVI popu-
lation requires OAC,1 a strategy that seems underused and that has
never been evaluated prospectively. Dual antiplatelet therapy
(DAPT) remains the most widely used antithrombotic strategy after
TAVI, being used in >60% of patients, while VKA is used in <20% of
patients,77 although AF is observed in >40% of TAVI patients.
Current recommendations are expert-driven, rather than evidence-
based (Table 6).
Up to 35% patients undergo coronary stenting prior to TAVI. In
such patients, the risk of stent thrombosis and/or ischaemic cardiac
events in addition to that of AF should be considered in the overall
risk assessment.82 Here triple therapy, a combination of a VKA, low-
dose aspirin and clopidogrel, is used in high risk patients, and associ-
ated with an increased risk of death, stroke, TE, or major bleeding
when compared to VKA alone.78,82 Such combinations should be
discussed in the context of recent (i.e. <6 months) acute coronary
syndrome and/or stent implantation, especially in the presence of an
unfavourable coronary anatomy (more than three stents, stent
length >_60 mm, multivessel disease, left main disease) but should be
avoided whenever deemed possible given the established better
safety and the possible preserved efficacy of a combination of war-
farin and clopidogrel in patients with AF undergoing drug-eluting
stent placement.83–85
Recent evidence suggests that VKA alone is much safer and pro-
vides a similar rate of ischaemic events as compared to VKA plus anti-
platelet therapy (aspirin) in patients undergoing TAVI.82 However
this study was observational, not randomized with an unbalanced
number of patients per treatment arm, and randomized confirmation
is needed. Therefore, the association of OAC with SAPT in AF
patients who underwent successful TAVI should be considered up to
one year when there is a recent ACS or a recent coronary stenting86
and when the bleeding risk is deemed low (Figure 2).
OAC alone as antithrombotic strategy is currently being tested
in three trials (POPular-TAVI NCT02247128, GALILEO
NCT02556203, ATLANTIS trial NCT02664649), while another trial
is testing aspirin alone or in combination with clopidogrel (ARTE
NCT02640794), although AF patients appear excluded. Indeed, the
benefit of VKA over DAPT in AF depends on the quality of INR con-
trol,76 and it has been modelled that a time in therapeutic
range >_58% would be needed to benefit from being on OAC rather
than on DAPT,76 which is probably not the case in the TAVI
population.
Subclinical valve thrombosis is another challenging issue as it may
may occur early after TAVI. Although the frequency of this poten-
tially ominous phenomenon remains undefined, as this condition is
difficult to detect, but it seems reversible with anticoagulation.
Whether it is associated with cerebrovascular events remains to be
established.87 Given all these uncertainties, ongoing trials are also
testing the anticoagulation hypothesis after successful TAVI irrespec-
tive of the need of OAC hypotheses using NOACs (NCT02556203,
NCT02664649) which have been shown to be better tolerated.
Figure 2 shows all currently recommended treatment options.
Recent observational evidence suggest the safety of FXa inhibition
in TAVI,88 showing the feasibility of NOAC in the post-TAVI setting.
However, results from randomized comparison of FXa inhibition vs.
other antithrombotic strategies are lacking.
Left atrial appendage occlusion
procedure
Following clinical trials,89–91 percutaneous endovascular left atrial
appendage occlusion (LAAO) has been increasingly developed and
performed worldwide for patients with AF, especially those with
contraindications to long-term OAC.92,93 This is supported by guide-
lines from the ESC, which give a class IIB recommendation for LAAO
in AF patients with high stroke risk and contraindications to long-
term OAC.4
Antithrombotic therapy following LAAO has not been well eval-
uated, and it is not even known whether OAC or antiplatelet therapy
or no therapy is preferable. When possible according to the patient
bleeding risk profile, after LAAO most centres use a 6-week period







are needed to define the role of
NOACs in this setting.
• The efficacy and safety of NOACs in
patients with non-rheumatic mitral
and/or aortic regurgitation or other
native VHD may be similar to AF
patients without VHD based on small
numbers of patients in post hoc analy-
ses of RCTs. More data are needed to
define the role of NOACs in this
setting.
9,66–72,77,78
• In patients with haemodynamically
insignificant valve disease and in those
who have had prior successful balloon
mitral valvulotomy, NOACs can be
considered as substitute for VKAs.
67,68,71–75,77
NB. Recommendations for TAVI are given in the specific section.
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and aspirin (75–325 mg) until the 6-months visit. Some patients may
also receive NOAC.94 Subsequently, low-dose aspirin alone is
continued indefinitely, as tested in the pivotal trials.89,90,95 This anti-
platelet regimen has never been compared with any long term
NOAC-based anticoagulation regimen.9,96 However, the ASAP study
showed that LAAO with the Watchman device is feasible and could
be safely performed without OAC cover (but with antiplatelet ther-
apy).95 Such strategy is being evaluated in the ongoing ADRIATIC
study (Apixaban versus Dual or single antiplatelet therapy to Reduce
Ischemic and bleeding events in Atrial fibrillation patients Treated
with Invasive Closure of the left atrial appendage). The ASAP TOO
randomized trial (NCT02928497) is currently establishing the safety
....................................................................................................................................................................................................................
Table 6 Recommendations for antithrombotic therapy during and after TAVI in the guidelines in patients with and
without indication for OAC




Post-procedural Aspirin 81 mg indefinitely
and Clopidogrel 75 mg





(75 mg/day) in the first
3 months
Low-dose Aspirin indefi-




in first 3 months after
TAVI
Patients with a clear
indication for OAC (as
in AF)











ACC, American College of Cardiology; ACT, activated clotting time; ACCP, American College of Chest Physicians; AF, atrial fibrillation; AHA, American Heart Association;
ASA, acetylsalicylic acid (aspirin); AVR, aortic valve replacement; CCS, Canadian Cardiovascular Society; ESC, European Society of Cardiology; INR, international normalized
ratio; VKA, vitamin K antagonists.
Figure 2 Proposed algorithm for AF patients undergoing a TAVI procedure (adapted from references 87). O refers to oral anticoagulation as VKA
(or possibly NOAC). ASC, acute coronary syndrome; CAD, coronary artery disease; DAPT, dual antiplatelet therapy; OAC, oral anticoagulant;
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and effectiveness of the LAAO vs. SAPT in patients with non-valvular
AF deemed not to be eligible for OAC to reduce the risk of stroke.
Consensus statements
Antithrombotic therapy for
valvular atrial fibrillation in
pregnant women
Valvular AF in pregnancy is relatively rare and can be due to congenital
heart disease, mitral valve prolapse with significant mitral regurgitation,
or to rheumatic heart disease. Valves can be repaired or replaced with
a mechanical valve prosthesis.97 Pregnancy by itself is a prothrombotic
state and the coalescence of venous stasis and hypercoagulability
results in nearly a five-fold increase in the risk of venous thromboemb-
olism during pregnancy.86 The goal of anticoagulation during pregnancy
should be to safely balance the maternal risk of TE and haemorrhage
with the foetal risk of exposure to VKA. The continuously changing
pharmacokinetics of LMWH during the various trimesters adds an
additional challenge and requires monitoring by peak and trough anti-
Xa levels,86 which is often not feasible (Figure 3).
Women of child-bearing age with VHD need to be comprehen-
sively counselled prior to valve replacement and pre-pregnancy to
decide on the most appropriate type of valve and to be made aware
of the teratogenicity and fetotoxicity of VKA, pregnancy-induced hae-
modynamic changes and the pre-existing hypercoagulable state
which can compromise foetal development and significantly increase
the risk of serious and/or fatal complications to both mother and
child.98 Women with mechanical prosthetic valves should ideally
have preconception evaluation, including advice on risk prediction
and contraception, by a joint cardiac-obstetric team seeking advice
from other specialties.97 Careful counselling on maternal and off-
spring risk should be done according the modified World Health
Organization classification and should include information on compli-
cations such as heart failure, valve thrombosis, bleeding complications
which can occur during, but also beyond the immediate delivery
period. Also, the consequences of the medication that may be
required (for example warfarin embryopathy) need to be discussed.
However, often women in some countries may present after
20 weeks of gestation, which has implications for their functional
assessment, harmful medication can’t be terminated timeously and
limits the option for pregnancy termination. Such cases are challeng-
ing and should be managed at tertiary centre where they can be
appropriately assessed and guided/treated. Since anticoagulation is
recommended in pregnant women with AF at risk of stroke, to mini-
mise teratogenic risk and intrauterine bleeding, the ESC guidelines
recommend that dose adjusted heparin should be used during the
first trimester of pregnancy and in the 2–4 weeks before delivery.4
VKA or heparin can be used in the remaining trimesters of the preg-
nancy.4 In the absence of adequate safety data, NOACs should be
avoided in pregnancy and in women planning a pregnancy4.
Consensus statements
Patient values and preferences,
and societal issues
Treatment decisions need to balance the benefits and risks of treat-
ment and manage realistic patient expectations, particularly in associ-
ation with co-morbidities and in pregnancy. These decisions are
complex and require assimilation of life expectancy, ability and will-
ingness to take anticoagulants, risk of bleeding, lifestyle, co-
morbidities, risk of re-operation, and patient preference.100–102
Clinical guidelines on the management of VHD100 advocate incor-
porating informed patient preferences into treatment decisions and
technological advances (for VHD) must be employed ‘responsibly
within a framework of care which enables shared decision making
and promotes patient goals and well-being’.103 This requires candid






• AF patients who underwent successful
TAVI may be treated with FXa inhibitors;
however data are limited.
9
• AF patients with stable coronary artery
disease who underwent TAVI may be
treated with OAC only, including VKA
and FXa inhibitors; however prospective
data are limited.
9,82,83
• Based on trial protocols, OAC and single
antiplatelet therapy after successful
LAAO may be used up to 6 weeks in low
bleeding risk patients, followed by single
antiplatelet therapy; however, long term
data are limited, nor any comparison with
NOACs.
89,90,95
• Single antiplatelet therapy or no antith-
rombotic therapy may be used after
LAAO in AF patients who are not eligible
for VKA; however, long term data are lim-







• There is no consensus on the optimal
regimen for anticoagulation in peri-
partum women with mechanical valve
prosthesis with AF.
86,97,99
• As the optimal anticoagulation regi-
men for use in pregnancy and peripar-
tum remains undetermined, all
decisions should be made by a fully
informed mother and partner in con-
sultation with a multidisciplinary team.
86,97,99
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treatment is not futile. Shared decision making103,104 requires patients
to be appropriately informed about treatment options and likely out-
comes, to have the type of patient-physician relationship where
patients feel able to ask questions and where physicians provide
information and communicate risk effectively,105,106 to enable
patients to make an informed decision incorporating their values,
goals and preferences.103,107,108 Patient’s treatment preferences are
likely to vary markedly, with patients often willing to accept higher
levels of risk.108 Patient decision-aids including micro-simulation
models are available for patients with VHD.109,110
Implications for low-to-middle income
countries
Valvular AF is more common in the Asian and African population
compared to their western counterparts mainly due to greater bur-
den of rheumatic heart disease.110,111,112 Stroke risk is higher among
patients with valvular AF (17–18%/year) compared to those with
non-valvular AF (4%/year).113 Further, AF may further increase the
risk of bioprosthetic valve thrombosis (see Supplementary material
online, Table S4).114 The burden of rheumatic valve disease is higher,
but the quality of anticoagulation is suboptimal in low and middle
income countries. Monitoring of the INR and follow-up remains poor
and significant proportion of patients present with sub-therapeutic
INR. The majority of these patients are young (median age
28 years),118 unemployed (75.3%) and women (51–66%)112,115 of
reproductive age. On average, they tend to be nearly 10–12 years
younger than their western counterparts. Many are unaware of the
concept of therapeutic range INR (60%) and few (<4%) are on con-
traceptives despite treatment with warfarin. The NOACs are expen-
sive and beyond the reach of the majority of patients requiring them
in these countries. Suboptimal anticoagulation and consequent
increased risk of stroke, may lead to significant disability adjusted life
years lost and this is likely to pose a major economic burden.
Strategies to improve awareness: (i) about the disease, (ii) medication
side-effects, (iii) importance of medication adherence and INR moni-
toring, and 4) the danger of anticoagulation during pregnancy are
scanty. Although point of care INR testing shows promise (see
Supplementary material online, Table S4), its use among patients from
the developing world needs to be determined. The impact of
NOACs is less certain, although one recent Brazilian study evaluating
NOACs in public health system context found that NOACs present
a lower cumulative cost per patient when compared to VKAs.116
Health economic perspectives
AF is a disease that induces significant consumption of resources and
costs, encompassing direct medical costs, associated with patient’s
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medical care (hospitalisations, medications, out-patient visits, etc.),
and direct non-medical costs (i.e. costs related to residential or social
care, as well as out of pocket expenses).117,118
Other costs that are usually taken into account in health-
economic analyses are productivity losses caused by patients’ inability
to work, or absence from work of relatives in order to provide infor-
mal care.119 In patients with AF direct costs, reported as per-patient
annual costs, have been estimated $2000 to 14 200 in North
America and 450 to 3000 Euros in Europe per patient.119
Patients with VHD who have AF require appropriate risk stratifica-
tion for stroke/SE and, when indicated, the consequent prescription
of OAC implies a difficult balance between the risk of stroke and sys-
temic TE and the risk of bleeding.120,121 Stroke and major bleeding
have also an economic effect. Indeed, the main drivers of costs in AF
patients are AF-related hospitalizations, stroke and haemorrhagic
events. For strokes occurring in patients with AF, the direct costs per
patient are approximately 33% greater than the costs of stroke not-
related to AF126 and are in the range of 30 000 Euros over a 2-year
period for a severe ischaemic stroke.123 The costs of intra-cerebral
haemorrhage is 50% higher than the cost of ischaemic stroke over a
1 year time course.124
Underutilization of, and non-adherence to, warfarin is also quite
common and is associated with increased costs,125,126 resulting from
TE and haemorrhagic complications. Improved adherence to OAC in
AF patients at risk of stroke is important in order to attain the full
clinical and economic benefit of thromboprophylaxis.
Non-vitamin K antagonist oral anticoagulants can be prescribed to
some subgroups of patients with VHD6,127,128 and a series of analyses
focusing on the cost-effectiveness of these agents vs. warfarin has
been published, although no study considered separately patients
with VHD. In general, despite the higher cost of NOACs as com-
pared to warfarin, the associated benefits make these agents
cost-effective in the long-term, especially in settings with poor antico-
agulation control associated with VKAs.129,130
Consensus statements
Summary and areas for future
research
Mechanical valve prostheses
Currently, patients with AF and a mechanical prosthesis should only
be treated with a VKA. Since the RE-ALIGN study, no other NOAC
(factor Xa inhibitor drug class) has been tested in this patient group.75
However, the thrombotic risk could be reduced once endothelial tis-
sue is present around the ring.17 A trial could potentially be designed
after endothelialization: the first 3 months with VKA, followed by a
randomized comparison between continuing VKA or switching to a
NOAC.
One trial proposed or ongoing with NOACs in patients with and
without AF, is the Comparison of Antithrombotic Treatments After
Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic




intervention, and transcatheter mitral
valve interventions
Usually, patients with a bioprosthesis and AF receive a VKA.
Pericardial valves are less thrombogenic than mechanical valve pros-
theses. Some physicians do not consider bioprostheses as a contra-
indication of NOACs. Before recommending a NOAC rather than
VKA for these patients, a randomized trial is needed. This is also the
case for patients undergoing valve repair.
Trans-aortic valve intervention corresponds to transluminal implan-
tation of a bioprosthesis and is being increasingly used. The antithrom-
botic treatment in patients with sinus rhythm and TAVI remains
controversial and the optimal treatment in patients with AF requiring
TAVI (as well as TMVI—see earlier section) is currently unknown.
A global study comparing a rivaroxaban-based anti-thrombotic
strategy to an antiplatelet-based strategy after TAVI to optimize
clinical outcomes (GALILEO) is currently ongoing.131 The two
arms consist of either rivaroxaban 10 mg once daily and aspirin
75–100 mg for the first 90 days, followed by rivaroxaban alone; or
clopidogrel 75 mg and aspirin 75–100 mg for the first 90 days, fol-
lowed by clopidogrel alone. Patients with current or previous AF
are excluded. The investigators assume that 15% of patients in
sinus rhythm at inclusion will develop AF during follow-up.
Treatment after new onset AF will be, in patients randomized to
rivaroxaban, a switch to rivaroxaban 20 mg OD or 15 mg OD for
those with moderate renal impairment and in those randomized
to clopidogrel, a switch to VKA (target INR 2–3).
Another ongoing study is the Anti-Thrombotic Strategy after
Trans-Aortic Valve Implantation for Aortic Stenosis (ATLANTIS)
study which is ongoing and plans to include 1509 patients after
successful TAVI procedure. Randomization will be stratified
according to the need for oral anticoagulant. Patients with an indi-
cation for OAC will be randomized 1:1 to VKA or apixaban 5 mg
b.i.d. The primary endpoint after 1 year follow-up is a composite
of death, myocardial infarction, stroke, systemic embolization,
intracardiac or bioprosthesis thrombus, episode of deep vein
thrombosis or pulmonary embolism, and major bleeding. Patients
with no indication for oral anticoagulant therapy will be random-
ized 1:1 to either apixaban 5 mg bid or antiplatelet therapy. Other
trials are also proposed or ongoing with NOACs in patients with
and without AF, include the RIvaroxaban for bioprosthetic







• Appropriate use of oral anticoagu-
lants, when clinically indicated, has
both a clinical and economic value
since underutilization and/or non-
adherence are associated with
adverse outcomes and increased
costs.
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The main phase III studies of NOACs have used variable criteria for
excluding valvular patients. Some studies (ROCKET-AF and
ARISTOTLE) only excluded patients with mechanical valve prosthe-
ses and significant (moderate to severe) mitral stenosis. The sub-
analyses did not show any differences in efficacy among patients with
and without VHD. In the ROCKET-AF, there was more bleeding on
rivaroxaban than on VKA in patients with VHD.
A report from the Loire Valley Atrial Fibrillation Project compared
the outcome of patients without any valve disease and those with
valve disease but did not include either valve prosthesis or mitral
stenosis. Although patients with VHD had a higher risk of stroke and
TE events on univariable analysis, the difference was no longer signifi-
cant after adjustment, in line with an older age and a higher
CHA2DS2-VASC score in patients with VHD.
128
However, post hoc analyses are only hypothesis generating. Large
RCTs are needed with NOACs in the setting of AS, non-rheumatic
AR and MR before the role of NOACs can be fully defined in this
setting.
Mitral stenosis
There has not yet been a randomized trial comparing VKA and
NOACs in these patients. The prevalence of rheumatic mitral steno-
sis has become low in Western countries but remains high in Eastern
Europe, India, Africa, South America, and south East Asia. In these
regions, the time in therapeutic range is only 35–44%, according to a
global AF registry.7 Randomized clinical trials comparing VKA with a
NOAC is highly welcomed and should preferably include patients
from these affected countries.
Supplementary material
Supplementary material is available at Europace online.
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